表紙
市場調査レポート

世界の慢性閉塞性肺疾患(COPD)市場

Global Chronic Obstructive Pulmonary Disease (COPD) Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 315302
出版日 ページ情報 英文 79 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
世界の慢性閉塞性肺疾患(COPD)市場 Global Chronic Obstructive Pulmonary Disease (COPD) Market 2014-2018
出版日: 2014年10月01日 ページ情報: 英文 79 Pages
概要

慢性閉塞性肺疾患(COPD)は、広義には気腫、慢性気管支炎、難治性喘息、気管支拡張症といった様々な進行性の肺疾患を指します。COPDの病因ははっきりしていませんが、遺伝要因や大気汚染などが原因の一部とされています。現状、この疾患を完治させる事が出来ないため、対処療法が主な治療法となっています。世界のCOPD市場は、2013年から2018年にかけて、5.69%のCAGRで拡大することが予測されています。

当レポートでは、世界における慢性閉塞性肺疾患(COPD)の現状と今後の動向、治療タイプ別および地域別の動向、市場の成長要因や課題、主要企業の分析などを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測

第7章 COPDの管理

  • ファイブフォース分析

第8章 治療タイプ別の市場区分

第9章 地理区分

  • 南北アメリカのCOPD市場
  • 欧州・中東・アフリカ市域のCOPD市場
  • アジア太平洋地域のCOPD市場

第10章 購入基準

第11章 罹患率と有病率

  • 米国
  • 欧州
  • アジア太平洋地域

第12章 パイプラインの概要

第13章 市場成長因子

第14章 成長因子とその影響

第15章 市場の課題

第16章 成長因子と課題の影響

第17章 市場動向

第18章 動向とその影響

第19章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
  • その他の有力ベンダー

第20章 主要ベンダーの分析

  • AstraZeneca plc
  • Boehringer Ingelheim
  • GlaxoSmithKline plc
  • Pfizer Inc.

第21章 関連レポート

目次
Product Code: IRTNTR4201

About COPD

COPD is a broad term that covers various progressive lung diseases including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It is a serious condition that restricts airflow in the lungs and is characterized by increasing breathlessness. The exact etiology of COPD is not understood; however, most cases of COPD are caused due to genetic factors and by inhaling pollutants, including fumes and chemicals. The disease cannot be cured; it can be only be managed and treated.

TechNavio's analysts forecast the Global COPD market to grow at a CAGR of 5.69 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global COPD market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs in the form of oral medications as well as inhalers for the treatment of COPD. The Global COPD market can be segmented into five: Medications, Oxygen Therapy, Surgery, Pulmonary Rehabilitation, and Lifestyle Changes.

TechNavio's report, the Global COPD Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global COPD market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Astra Zeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Pfizer

Other Prominent Vendors

  • Alere
  • Almirall
  • Astellas Pharma
  • Axis Shield
  • Beckton Dckinson
  • Biosensors International
  • Dainippon Sumitomo Pharma
  • Medtronic
  • Merck
  • Mylan
  • Novartis
  • Siemens Healthcare Diagnostics
  • Takeda Pharmaceutical
  • Theravance

Market Driver

  • Elderly Population

For a full, detailed list, view our report

Market Challenge

  • High Cost of COPD Treatment

For a full, detailed list, view our report

Market Trend

  • Increase in Awareness of COPD

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast

07. Management of COPD

  • 07.1. Five Forces Analysis

08. Market Segmentation by Type of Treatment

09. Geographical Segmentation

  • 09.1. COPD Market in Americas
    • 09.1.1. Market Size and Forecast
  • 09.2. COPD Market in the EMEA Region
    • 09.2.1. Market Size and Forecast
  • 09.3. COPD Market in the APAC Region
    • 09.3.1. Market Size and Forecast

10. Buying Criteria

11. Rate of Incidence and Prevalence

  • 11.1.1. US
  • 11.1.2. Europe
  • 11.1.3. Asia

12. Pipeline Snapshot

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2013
  • 19.3. Other Prominent Vendors

20. Key Vendor Analysis

  • 20.1. AstraZeneca plc
    • 20.1.1. Key Facts
    • 20.1.2. Business Description
    • 20.1.3. Business Segmentation
    • 20.1.4. Business Strategy
    • 20.1.5. Revenue by Business Segmentation
    • 20.1.6. Revenue Comparison 2011-2013
    • 20.1.7. Sales Revenue by Geographical Segmentation
    • 20.1.8. Key Developments
    • 20.1.9. SWOT Analysis
  • 20.2. Boehringer Ingelheim
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation by Revenue 2013
    • 20.2.4. Business Segmentation by Revenue 2012 and 2013
    • 20.2.5. Geographical Segmentation by Revenue 2013
    • 20.2.6. Business Strategy
    • 20.2.7. Recent Developments
    • 20.2.8. SWOT Analysis
  • 20.3. GlaxoSmithKline plc
    • 20.3.1. Key Facts
    • 20.3.2. Business Overview
    • 20.3.3. Business Segmentation
    • 20.3.4. Business Segmentation by Revenue 2012 and 2013
    • 20.3.5. Sales by Geography
    • 20.3.6. Pipeline Products
    • 20.3.7. Business Strategy
    • 20.3.8. Key Information
    • 20.3.9. SWOT Analysis
  • 20.4. Pfizer Inc.
    • 20.4.1. Key Facts
    • 20.4.2. Business Description
    • 20.4.3. Business Segmentation
    • 20.4.4. Revenue by Business Segmentation
    • 20.4.5. Revenue Comparison 2012 and 2013
    • 20.4.6. Sales by Geography
    • 20.4.7. Business Strategy
    • 20.4.8. Key Developments
  • 20.5. SWOT Analysis

21. Other Reports in this Series

List of Exhibits:

  • Exhibit 1:Market Research Methodology
  • Exhibit 2:Global COPD Market 2013-2018 (US$ billion)
  • Exhibit 3:Global COPD Market Segmentation by Type of Treatment
  • Exhibit 4:Global COPD Market Segmentation by Drug Class
  • Exhibit 5:Global COPD Market Segmentation by Drug Class 2013
  • Exhibit 6:Global COPD Market by Geographical Segmentation 2013
  • Exhibit 7:COPD Market in Americas 2013-2018 (US$ billion)
  • Exhibit 8:COPD Market in the EMEA Region
  • Exhibit 9:COPD Market in the APAC Region
  • Exhibit 10:Global COPD Market by Geographical Segmentation 2013-2018 (in percent)
  • Exhibit 11:Global COPD Market by Geographical Segmentation 2013-2018 (in revenue)
  • Exhibit 12:AstraZeneca plc: Business Segmentation
  • Exhibit 13:AstraZeneca plc: Revenue by Business Segmentation2013
  • Exhibit 14:AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
  • Exhibit 15:AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 16:Boehringer Ingelheim: Business Segmentation by Revenue 2013
  • Exhibit 17:Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 18:Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
  • Exhibit 19:GlaxoSmithKline plc: Business Segmentation 2013
  • Exhibit 20:GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 21:GlaxoSmithKline plc: Sales by Geography 2013
  • Exhibit 22:GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 23:Pfizer Inc.: Business Segmentation
  • Exhibit 24:Pfizer Inc.: Revenue by Business Segmentation 2013
  • Exhibit 25:Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
  • Exhibit 26:Pfizer Inc.: Revenue by Geography 2013
Back to Top